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ABSTRACT: Venomous snakebites cause >100 000 deaths every year, in many cases
via potent depression of human neuromuscular signaling by snake α-neurotoxins.
Emergency therapy still relies on antibody-based antivenom, hampered by poor
access, frequent adverse reactions, and cumbersome production/purification.
Combining high-throughput discovery and subsequent structure−function character-
ization, we present simple peptides that bind α-cobratoxin (α-Cbtx) and prevent its
inhibition of nicotinic acetylcholine receptors (nAChRs) as a lead for the
development of alternative antivenoms. Candidate peptides were identified by
phage display and deep sequencing, and hits were characterized by electro-
physiological recordings, leading to an 8-mer peptide that prevented α-Cbtx
inhibition of nAChRs. We also solved the peptide:α-Cbtx cocrystal structure, revealing that the peptide, although of unique primary
sequence, binds to α-Cbtx by mimicking structural features of the nAChR binding pocket. This demonstrates the potential of small
peptides to neutralize lethal snake toxins in vitro, establishing a potential route to simple, synthetic, low-cost antivenoms.
■ INTRODUCTION
Snakebite envenoming kills or maims hundreds of thousands of
people every year,1,2 and loss of livestock is also emerging as a
substantial problem.3 Treatment requires rapid transport to a
medical facility and intravenous administration of antivenom, a
mix of immunoglobulin G antibodies isolated from, e.g., horse or
sheep immunized with snake venom.1 As the only effective
treatment, antivenoms save numerous lives but have the
disadvantages of time-consuming and expensive production,
poor access for those in need, and alarming numbers of adverse
reactions.4−6 There is therefore an urgent need for novel
treatments and new strategies, reflected in growing attention
from the World Health Organization.7,8
In the case of elapid snakes, such as cobras and kraits, three-
finger α-neurotoxins such as α-cobratoxin (α-Cbtx) and α-
bungarotoxin (α-Bgtx) are the most prominent and lethal
venom components.9−11 α-Cbtx and α-Bgtx potently inhibit
postsynaptic nicotinic acetylcholine receptors (nAChRs), which
depresses neuromuscular signaling, causing paralysis and loss of
respiration.12 The effectiveness of conventional antivenoms is
limited by immunogenicity, abundance of α-neurotoxin anti-
bodies in the immunized animal at the time of production,13 and
which type of snake inflicts the bite. Newer antibody-based
strategies have emerged, with a focus on smaller, less
immunogenic, and venom-specific antivenoms. Smaller camelid
antibody fragments raised against cobra venom were shown to
neutralize the effects of α-Cbtx in mice and may allow for greater
tissue penetration than conventional antivenoms.14 Phage
display of a library of human-derived antibody single-chain
variable fragments against α-Bgtx from krait venom led to one
fragment that neutralized toxin injected into mice.15 In the
future, combinations of such lead entities could enable
development of safe and effective treatments, as reflected in
the recent application of cocktails of human monoclonal
antibodies targeting mamba toxins.16 These showed promising
neutralization of dendrotoxins in mice, although some improve-
ment is needed in neutralizing α-neurotoxins.
As an alternative to antibody-based strategies, we sought to
discover short peptide-based neutralizers of α-Cbtx by screening
phage display peptide libraries for α-Cbtx binders. Hits were
then tested for neutralization of α-Cbtx inhibition of nicotinic
nAChRs using electrophysiology. This led to the identification
of an effective 8-mer peptide, for which we solved the peptide:α-
Cbtx X-ray cocrystal structure, revealing the detailed binding
mode. The identification and characterization of short peptide
neutralizers of α-Cbtx could lead to the development of targeted,
fully synthetic, next-generation antivenoms for snakebite
envenoming.
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Table 1. Phage Display Hits, Derivatives Thereof, and Their Prevention of α-Cbtx Inhibition of nAChRs
peptide sequence fold prevention of α-Cbtx inhibitiona affinityb identified by
no peptide (α-cbtx alone) 1.0
1 Ac-HAKTYMWDGWYMPTSH-NH2 7.4 2 ± 2 μM phage display
c
2 Ac-HVNTYMWDGRYMRTSH-NH2 1.0 phage display
c
3 H-NWAPAQHGQKWYMQDYTSLE-NH2 3.8 phage display
d
4 H-TSNTTPWQTSWELMYAQQNY-NH2 1.6 phage display
d
5 H-KPHTYINDHNFIQYDNQQWL-NH2 not soluble phage display
d
6 H-YVTHPWIDWWDNEPYM-NH2 not soluble phage display
d
7 H-GHHHRVYMTDVTEHFRWMGK-NH2 0.6 phage display
d
8 H-GHHHRVYMTDVTEHFRWWVN-NH2 0.5 phage display
d
9 TAMRA-HAKTYMWDGWYMPTSH-NH2 not tested 52 ± 3 μM optimization
10 Ac-TYMWDGWYMPT-NH2 4.5 optimization
11 Ac-YMWDGWYM-NH2 6.9 optimization
12 [PEG]6-YMWDGWYM-NH2













aα-Cbtx (40 nM) inhibited ACh (100 μM) gated currents through nAChRs to 8 ± 2% their control level, which is here normalized to 1.0. In the
presence of, e.g., peptide 1 (100 μM), α-Cbtx (40 nM) only inhibited ACh (100 μM) gated currents to 60 ± 18% of control, here normalized to
7.4-fold prevention of inhibition. bKd value of 9 determined in fluorescence polarization (FP) saturation experiment (n = 2). Ki values for peptides 1
and 12 determined by inhibition of 9 binding to α-Cbtx in FP competition experiments (n = 6), only measured for two lead peptides. cAfter five
rounds of selection by biopanning. dFrom deep sequencing of all phages. ePEG, polyethylene glycol. fNal, 3-(2-naphthyl)-L-alanine.
Figure 1. Peptide 1 prevents α-Cbtx inhibition of nAChRs. (A) Example two electrode voltage clamp recordings of ACh-gated currents in Xenopus
laevis oocytes expressing L247V mutant α7 nAChRs and RIC-3 (see Experimental Section, Electrophysiological Assays). In testing peptides, ACh was
applied for 10 s in regular conditions (“control”), three times after the application of either α-Cbtx (blue bars) or α-Cbtx with peptide (blue and
magenta bars; “App 1−App 3”), and then three more times to observe washout of any effects (“Wash 1−Wash 3”). (B) Mean ± SEM ACh-gated
current amplitude, normalized to control (“I/Icontrol”). Each peptide was tested with α-Cbtx on at least three oocytes: n (magenta columns) = 3−4. α-
Cbtx alone was tested on the same day on at least two oocytes: n (blue columns) = 2 (peptides 1 and 2) − 4 (all others).
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■ RESULTS
High-Throughput Identification of Peptide Binders of
α-Cbtx. Seeking novel binders of α-Cbtx, we screened naiv̈e
phage display libraries containing ≥1 × 109 disulfide-con-
strained 7-mers and linear 7-mers, 12-mers, 16-mers, or 20-mers
against immobilized α-Cbtx from Naja kaouthia (monocled
cobra). Isolation and sequencing of the most prevalent phages
after five rounds of biopanning identified two 16-mers, peptides
1 and 2 (Table 1). Additionally, deep sequencing of phages from
all rounds identified six additional prevalent peptides, 3−8, that
were also considered further (Table 1; see Experimental
Section).
Characterization of Peptides with YM Motifs That
Modulate α-Cbtx Inhibition of Nicotinic Acetylcholine
Receptors. We next tested these binders for functional
modulation of α-Cbtx activity in electrophysiological assays.
We heterologously expressed nicotinic α7-homomeric nAChRs
in Xenopus laevis oocytes and measured acetylcholine-gated
currents in response to acetylcholine alone, in the presence of α-
Cbtx, or in the presence of α-Cbtx preincubated with the
identified peptides. As expected, α-Cbtx alone (40 nM)
inhibited nAChR responses to ∼10% compared to the control
level, and washout of this effect was minimal, with subsequent
responses to ACh in the absence of α-Cbtx recovering to only
20% (Figure 1A,B). In the presence of peptide 1 (100 μM), α-
Cbtx (40 nM) only inhibited responses to ∼50% of the control
level, with responses after washout reaching 70% (Figure 1A,B).
Peptide 1 thus appears to prevent the effects of α-Cbtx. Peptide
2 had no effect on α-Cbtx inhibiting nAChRs (Figure 1B).
Among the six additional binders, peptide 3 prevented α-Cbtx
inhibition of nAChRs comparably to 1 (Figure 1B). However,
peptide 4 showed no effect (Figure 1B), and peptides 5 and 6
were poorly soluble and could not be tested. Curiously, peptides
7 and 8 enhanced both the onset and the washout of α-Cbtx
inhibition of nAChRs (Figure 1B). Thus, for two of the eight α-
Cbtx binders identified by phage display, the desired effect of
preventing α-Cbtx inhibition of nAChRs could be demon-
strated, and the shorter peptide 1 was chosen for the further
investigations.
We next established the dose-dependency of the effects of 1
on α-Cbtx in our electrophysiological assay. The initial
protection from α-Cbtx inhibition (“IApp3/IControl”) occurred at
concentrations of 1 in the range 30−100 μM, whereas apparent
enhancement of α-Cbtx washout (“IWash3/IControl”) occurred at
concentrations of 1 between 3−30 μM (Figure 2A). To better
estimate binding affinity, we turned to a fluorescence polar-
ization (FP) assay, for which we generated peptide 9, a
rhodamine dye-labeled derivative of peptide 1 (Figure 2C).
From incubating 9 in increasing concentrations of α-Cbtx, we
determined the dissociation constant for the α-Cbtx−9
interaction (Kd 52 ± 3 μM, n = 2, Figure 2D). By incubating
premixed α-Cbtx (40 μM) and 9 (50 nM) with increasing
concentrations of 1, we determined an IC50 value of 29 ± 6 μM
for compound 1 (n = 6, Figure 2E), corresponding to a Ki value
of 1.9 μM (see Experimental Section, Fluorescence Polarization
Assay). Regarding concentrations of 1 that elicited functional
effects, this Ki is more consistent with the enhanced washout of
α-Cbtx than with the prevention of α-Cbtx inhibition.
Peptide Aromatic Side Chains Bind to α-Cbtx Key
Residues R33 and D27. Seeking insight into the peptide−α-
Cbtx interaction, we turned to structure determination by X-ray
crystallography. This required improved peptide solubility, and
we therefore designed and tested truncated (peptides 10 and
11) and truncated, polyethylene glycolated (PEG6-ylated,
peptides 12−16) derivatives of 1 (Table 1, Supporting
Information, Figure S1). The PEG6-ylated 8-mer, peptide 12,
exhibited similar potency to 1 in electrophysiological assays,
with 12 (100 μM) restoring α-Cbtx (40 nM) inhibited ACh-
gated currents from ∼10% to ∼50% (Figure 2B). In the FP
assay, 12 outcompeted 9 from α-Cbtx similarly to 1, despite
slightly reduced affinity compared to 1 (12 Ki = 26 ± 4 μM, n =
6, P < 0.003, Figure 2E). We also observed increased stability of
12 compared to 1 at both room temperature and at 37 °C
(Supporting Information, Figure S2). Given the similar
functional properties but improved solubility of 12, it was
used for X-ray crystallography.
We obtained diffraction-quality cocrystals and solved the X-
ray crystal structure of the 12:α-Cbtx complex at 1.9 Å
resolution (Supporting Information, Table S1). The asymmetric
unit contains four copies of α-Cbtx and two copies of 12 (Figure
3A). One molecule of 12 binds to two toxin molecules
(designated α-Cbtx-A and α-Cbtx-B), forming a 1:2 complex
(Figure 3A, Supporting Information, Figure S3). The two α-
Cbtx-A:12:α-Cbtx-B complexes present in the asymmetric unit
are related by noncrystallographic symmetry and highly similar
Figure 2. Concentration dependence of peptide activity. (A,B)
Electrophysiological experiments as per Figure 1A, but here only initial
ACh application (“Control”), the third ACh application after peptide +
α-Cbtx (40 nM) (“App 3”), and the third ACh application after
washout (“Wash 3”) are shown. Mean ± SEM (n = 3) are shown to the
right. (C) Chemical structure of 9. (D) Fluorescence polarization of 9
(50 nM) by increasing concentrations of α-Cbtx. Mean ± SEM, n = 2.
(E) Concentration-dependent displacement of 9 (50 nM) from α-Cbtx
(40 μM) by compound 1 and 12. Mean ± SEM, n = 6.
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to a root mean square deviation (rmsd) of 0.2 Å. Thus, we
observed two different binding modes of 12with α-Cbtx (Figure
3B,C). Whereas the structure of α-Cbtx-B is very similar to the
conformation of α-Cbtx observed in previous crystal structures,
12 binding induces substantial structural rearrangements of loop
II and indirectly also of loop III in α-Cbtx-A (Figure 3D,E). The
formation of a 1:2 12:α-Cbtx complex was surprising
considering that 12 was added in 1.2-fold molar excess in the
crystallization set-ups. This raises the possibility that the
mechanism of α-Cbtx inhibition by 12 involves inducing toxin
dimerization. There is very little contact between the two α-Cbtx
molecules themselves in the complex (52 Å2) as determined by
computational analysis (PISA),17 suggesting that these inter-
actions do not contribute to the stabilization of the complex. We
reasoned that if both motifs A and B were acting independently
as inhibitors, they should prevent α-Cbtx inhibition of nAChRs
on their own. However, shorter peptides designed to include
only binding motif A (peptides 13 and 14) or motif B (peptides
15 and 16) did not have any effect on α-Cbtx activity in
electrophysiological assays (Table 1, Supporting Information,
Figure S1). We therefore tentatively conclude that the
simultaneous binding of 12 to two α-Cbtx molecules leads to
amutual stabilization of both interfaces or that peptide 12 blocks
α-Cbtx by linking two α-Cbtx molecules and preventing them
from further binding to nAChRs. However, analysis of 12-
induced dimerization of α-Cbtx in solution by size exclusion
chromatography was not possible due to the high hydro-
phobicity of the peptide, which led to aggregation on the gel
filtration column.
Although binding modes A and B are distinct, they share
common features (Figure 3B,C, Table 2). (i) Two different YM
Figure 3. Structure of the 12:α-Cbtx complex (PDB 6ZFM). (A) Asymmetric unit of the 12:α-Cbtx crystal structure. Each molecule of 12 (magenta)
binds two toxin molecules A and B (light and dark cyan, respectively). A second α-Cbtx-A:12:α-Cbtx-B complex in the asymmetric unit is related by
noncrystallographic symmetry. (B) Magnified view showing interaction of α-Cbtx loop II (light cyan) with 12 (magenta) in binding mode A. Two
alternative conformations for the side chain of 12M2 were modeled. Key interacting amino acid residues shown in stick representation and labeled.
Cation−π-stacking interactions and hydrogen bonds are highlighted by dashed and dotted lines, respectively. (C) Bindingmode B, with secondα-Cbtx
molecule (dark cyan), from same structure with interacting residues drawn as in (B). (D) Binding mode A leads to conformational changes in α-Cbtx
(light cyan) compared to the structure observed of α-Cbtx fromNaja naja siamensis (dark gray, PDB 2CTX, root-mean-square deviation (rmsd) 1,31
Å), Naja naja oxania (light gray, PDB 1NTN, rmsd 1.7 Å), or Naja naja kaouthia in complex with AChBP (green, PDB 1YI5, rmsd 1.47 Å). The
greatest displacement is observed in loop II (11 Å) and loop III (4.7 Å). (E) Binding mode B (cyan) resembles more closely previously reported
structures of α-Cbtx from Naja naja siamensis (dark gray, rmsd 1,07 Å), Naja naja oxania (light gray, rmsd 0.67 Å), or Naja naja kaouthia in complex
with AChBP (green, rmsd 0.87 Å). (F) Interaction of α-Bgtx (blue) loop II with the principal (α subunit) and complementary (δ subunit) faces of the
muscle nAChR (pink, PDB 6UWZ). Key interacting residues drawn as in (B).
Table 2. Key Residues of the 12−α-Cbtx Interaction (PDB
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motifs bind at equivalent positions in binding mode A and B,
forming a hydrogen bond between 12Y7 or 12Y1 and α‑CbtxD27
and interacting with the surface of α-Cbtx at the beginning of
loop II. (ii) Using different aromatic residues, modes A and B
both create, together with α‑CbtxF29, an aromatic pocket for
α‑CbtxR33 through extensive cation−π stacking interactions of
parallel and T-shaped geometry (Figure 3B,C). Thus, the key
residue α‑CbtxR33 that has been implicated in penetrating the
ACh binding pocket of nAChRs18 is tightly blocked by 12 in
both binding modes. In binding mode A, a tryptophan residue
that precedes the YMmotif also interacts with α‑CbtxF65 at the C-
terminus of α-Cbtx and forms a hydrogen bond to the backbone
carbonyl of α‑CbtxP7 (Figure 3B). Exchange of this tryptophan for
arginine (along with three other substitutions) in peptide 2 led
to a loss of the preventive activity of the peptide (Table 1, Figure
1B), underscoring the functional importance of this tryptophan
residue.
The Inhibitory Peptide Mimics the α-Cbtx Interaction
Site and Binding Mode of the nAChR. The structure of the
nAChR:α-Cbtx complex has not been determined, but the
structure of the muscle-type (heteromeric α−γ−α−δ−β)
nAChR:α-Bgtx complex was recently reported.19 Because α-
Cbtx and α-Bgtx share high sequence and structural
homology,18 we can use the nAChR:α-Bgtx complex to compare
α-Cbtx interactions with the peptide inhibitor to those with its
native target (Figure 3F). The nAChR:α-Bgtx interaction is
much more extensive (∼1100 Å2) compared to the 12:α-Cbtx
complex (∼440 Å2 in mode A and ∼510 Å2 in mode B), but
interestingly, the peptide inhibitor 12 partially mimics the
binding site of the natural substrate. Most strikingly, 12Y1 (in
binding mode B) and 12Y7 (in binding mode A) adopt the same
position as nAChRαY190, which forms a conserved hydrogen bond
with α‑CbtxD27 and α‑BgtxD30, respectively (Table 2). This
interaction is also conserved in the complex of α-Cbtx with the
acetylcholine binding protein (AChBP),20 where AChBPY185
binds α‑CbtxD27 (Supporting Information, Figure S4A). The
similarity between 12 and nAChR is also apparent in the pocket
for α‑CbtxR33/α‑BgtxR36 and α‑CbtxF29/α‑BgtxF32 in binding mode
A, which is formed by aromatic side chains 12W3/12Y7 in 12-A
and nAChRαY190/nAChRαY198 in the nAChR. In contrast,
12Y1/12W6 in 12-B are also engaged in cation−π interactions
with α‑CbtxR33, but the orientations of side chains differ from
nAChR:α-Bgtx. The aromatic pocket for α‑BgtxR36 is closed by
ynAChRγW55 /nAChRγδW57 and nAChRαW149 through hydro-
phobic interaction, which lacks a counterpart in the 12:α-Cbtx
complex. It is also interesting to note that aspartate nAChRαD200
superposes with 12D4 of binding mode A. nAChRαD200 does not
play a role in α-Bgtx binding to the receptor, but the substitution
of α‑BgtxV39 to α‑CbtxR36 likely leads to the formation of a salt
bridge upon binding of α-Cbtx to the nAChR. Thus, 12D4would
further imitate the target binding site. Taken together, the
structural comparison reveals that the phage display selection
provided a peptide that blocks the binding site of α-Cbtx by
imitating the cognate interface through an unrelated sequence.
■ DISCUSSION
The urgent need for alternatives to conventional antivenom for
snakebite has given rise to a handful of novel approaches,
including camelid- and human-derived antibodies that target
particular venom components,14−16,21 nanoparticles to adsorb
plasma proteins,22 and small molecules or peptides to inhibit key
components of venom.23,24 Smaller peptides are likely cheaper
than traditional antivenom and may lead to more convenient
and effective drugs that can be injected subcutaneously.7,25
Consequently, we pursued the idea that short, synthetic peptides
inhibiting critical toxin−receptor interactions could serve as lead
compounds for the development of novel peptide-based
antivenoms. Furthermore, our results suggest that such small
peptides are conducive to crystallization and rational design and
could be useful for the academic community as pharmacological
tools. Starting from some five billion 7-mers, 12-mers, 16-mers,
and 20-mers, we arrived at an 8-mer that prevents α-Cbtx from
inhibiting nicotinic nAChRs.
Our initial search identified eight peptides that bound α-Cbtx.
Despite the absence of primary sequence homology with
nAChRs, each peptide contained at least one YM motif. The
tyrosine forms a hydrogen bond to α‑CbtxD27, and this Y−D
bond is conserved in both peptide binding modes that we
observed in AChBP:α-Cbtx and nAChR:α-Bgtx structures19,20
and also in a nAChR-like 13-mer binding to α-Bgtx26
(Supporting Information, Figure S4B), suggesting that this
tyrosine residue represents an essential feature for α-Cbtx-
binding peptides. The methionine occupies a unique binding
site at the base of α-Cbtx loop II that might be exploited in future
optimizations. Remarkably, the YM motif is flanked by a
tryptophan in the two peptides (and derivatives thereof) that
had the desired effect of preventing nAChR inhibition by α-
Cbtx. The YM sequence in combination with an upstream or
downstream tryptophan residue thus represents a novel motif
that might serve as a scaffold for designing future peptide
inhibitors or peptide-derived small molecule inhibitors of α-
Cbtx. Simultaneous binding of our inhibitor to two α-Cbtx
molecules seems to be required for functionality. This is evident
in the inhibition of α-Cbtx by peptides 1, 10, 11, and 12, which
contain both motifs A and B of 12, while peptides 13−16, which
contain either motif A or motif B of 12, fail to inhibit α-Cbtx. We
suspect that binding of two α-Cbtx molecules results in
stabilization of the peptide conformation. Introducing dimeriza-
tion of α-Cbtx might also be part of the inhibitory mechanism of
the identified peptides. Thus, strategies to rigidify the two
identified epitopes might be employed for improved activity.
Optimization will also require improved affinity for α-Cbtx, as
half-maximal effective concentrations and Ki values for our 8-
mer, 16-mer, and 20-mer inhibitors were in the low micromolar
range. Much greater affinity for α-Bgtx was seen with previously
studied 13-mers,24 possibly due to greater stability through the
additional intramolecular hydrogen bonds afforded by the β-
hairpin structure of those peptides. Although also identified
through phage display, those peptides bear striking similarity to
the principal face of nAChRs.24 Our identification of a nAChR-
unrelated sequence with a mimicking effect opens up entirely
new avenues for future work. It is also noteworthy that, in
addition to inhibitors of α-Cbtx, we also identified enhancers of
α-Cbtx activity, tentatively suggesting that toxin activity can be
manipulated by peptides via distinct mechanisms. The desired
improvement of affinity of 1, 12, and similar molecules from the
present study may be possible through subtle modifications. In
limited structure−activity relationship experiments, we ob-
served that single substitutions of D4 and W3 to glutamic acid
and naphthylalanine, respectively, yielded two peptides, 17 and
18, that retained the inhibitory effect on α-Cbtx (Table 1,
Supporting Information, Figure S1B). Tolerance of isofunc-
tional substitutions at W3 and D4, which indeed interact with
α‑CbtxR33 and α‑CbtxR36 (Figure 3B), suggests some scope for
optimization at these positions.
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That PEGylation was also well tolerated could prove useful in
future antivenom drug development. Weaknesses of peptide-
based drugs include short in vivo half-life/rapid elimination and
poor membrane permeability.25 However, these can sometimes
be overcome by increasing molecular mass via PEGylation and
conjugation to larger peptides or other moieties.27−29 The fact
that the YMWDGWYM motif was effective on its own (as 11),
PEGylated (as 12), straddled by other residues (in 1), or even as
a divergent, longer peptide (as 3) is also promising when
considering typical approaches to improve stability and
membrane permeation, such as cyclization, stapling, and
conjugation.30,31 Ourmeasurements of peptides 1 (free peptide)
and 12 (PEGylated) in phosphate-buffered saline show that
both are reasonably stable over the course of 1 day, and notably,
the purity of 12 was decreased by just 7% after incubation for 9
days at room temperature or 2 days at 37 °C (Supporting
Information, Figure S2).
■ CONCLUSION
Current therapies for snakebite envenoming are difficult to
produce, far too inaccessible for those in need, and often cause
adverse reactions.1,32 We speculate that a combination of several
peptides targeting the key venom components will provide
simpler, more distributable, safer, and subcutaneous- and/or
intramuscular-capable alternatives to conventional antivenom,
or at least a feasible short-term solution that prevents excess
toxin from reaching nAChRs immediately after snakebite. Our
report on the identification of such snake toxin-binding peptides,
which we term “serpentides”,33 the characterization of their
effects on the physiological action of the toxin, and the high-
resolution structural characterization of the peptide−toxin
interaction should facilitate future endeavors in developing
such molecules into therapies.
■ EXPERIMENTAL SECTION
Phage Display Screening. Maleic anhydride activated 96-well
plates (ThermoFisher Scientific) wells were incubated with 100 μL of
10.0 μM α-cobratoxin (≥99%, from Naja kaouthia, Latoxan) in
phosphate buffered saline (PBS) or PBS alone (as control), capped with
200 μL 10% (v/v) ethanolamine, for 1 h at room temperature (RT,∼21
°C) and then overnight at 4 °C. Subsequently, the wells were washed
3× with 200 μL of 0.05% Tween-20 (PBST) and 2× with 200 μL of
PBS. Wells were then blocked by incubation in 100 μL blocking buffer
(0.1 M NaHCO3 pH 8.6, 0.02% NaN3, 0.1 μg/mL streptavidin
(incidental, as the selection process did not utilize biotinylation), 5 mg/
mL bovine serum albumin at RT on a plate shaker for 2 h. Wells were
then washed 10× with PBST and 2× with PBS to remove excess
blocking agent.
For the first biopanning round, 2.5 μL of both TriCo-16 and TriCo-
20 libraries (Creative Biolabs) were combined in 105 μL of blocking
buffer and incubated for 30 min at RT. This phage solution (100 μL)
was transferred to a blocked but not α-cobratoxin-coated MaxiSorp
plate and incubated for 1 h at RT to remove unspecific binding phages.
Unbound phage (100 μL) was then transferred to the α-cobratoxin-
coated wells and incubated for 1 h at RT. The solution was then
removed, and wells were washed 10x PBST and 2× with PBS. Bound
phages were eluted by incubating for 10 min with triethylamine (200
μL, 100 mM) followed by neutralization with a solution of Tris-HCl
(400 μL, 1 M, pH 7.4). Before each of four subsequent rounds of
selection, the eluted phages were amplified in 2xYT medium (8−10
mL) overnight at 37 °C after infecting TG1 Escherichia coli. Amplified
phages were precipitated using PEG6000/NaCl and concentrated in PBS
(300 μL). Phages (115 μL) mixed with blocking buffer were incubated
for 1 h in aMaxiSorp well before the next round of panning. The specific
binder/control ratios (based on numbers of plaque forming units) were
24, 203, 755, and 175 for rounds two through five, indicating that
specific α-Cbtx binders had been amplified (except in the final round).
Twenty-four single plaques were picked and amplified overnight,
centrifuged for 10 min at 8000 g, and 125 μL supernatant was added to
α-Cbtx-coated wells for overnight incubation. The solution was then
removed, and wells washed, blocked, and washed again, and each eluate
(100 μL in PBS) was mixed 1:1 with blocking buffer. 100 μL was added
to α-Cbtx-coated (or control) wells, incubated for 1 h at RT on a plate
shaker, and then washed 10× with 100 μL PBST and 2× with PBS.
Bound phages were then incubated in 100 μL of a solution of
monoclonal horseradish peroxidase (HRP) conjugated anti-M13 phage
antibody (GE Healthcare) diluted 1:100 in blocking buffer, for 1 h on a
plate shaker, washed again (10× with PBST, 2× with PBS), and each
well was incubated in 100 μL HRP substrate (ortho-phenylenediamine
(OPD, Dako, 2 mg in 3 mL water) with 5 μL H2O2) for ∼30 min.
Reactions were stopped by the addition of 100 μL of 0.5 MH2SO4, and
absorbance (490 nm) was measured (VersaMax Tunable microplate
reader, Molecular Devices). Empty wells were used as blank controls for
subtraction of signal. The 12 clones that gave the highest responses in
the ELISA were selected for further processing. They were amplified
overnight and PEG6000/NaCl precipitated. ssDNA was isolated and
Sanger sequenced (Eurofins Genomics). Eleven encoded the same
peptide, 1, and the remaining encoded 2, which is 75% identical to 1
(Table 1).
Deep Sequencing of Phage Libraries and Selection of an
Additional Six Peptides for Testing. Amplified phage eluates from
biopanning rounds one, two, three, and five were used for deep
sequencing of variable regions along with rounds two, three, four and
five for the control selections. The libraries after those rounds were
PCR amplified with barcoded primers (based on the above phage
libraries and according to suppliers’ instructions), gel purified, and
sequencing adapters were ligated onto the DNA using the Ion Plus
fragment library kit (ThermoFisher Scientific). Finally, the DNA was
ligated to Ion Sphere Particles, subjected to emulsion PCR according to
the Ion OneTouch 200 protocol. The Ion Sphere Particles were loaded
onto an Ion 318 chip and sequenced in an Ion Torrent Personal
Genome Machine system. The phage sequences were extracted, split
according to barcodes and converted to peptide reads. For unknown
reasons, the sequencing failed for the fifth biopanning round against α-
Cbtx as well as the second biopanning round for the control. The
number of peptides allocated to these samples were <400 compared to
>100 000 for the remaining six samples. Accordingly, these samples
were disregarded in further analyses. A total of 1,469,811 sequences
were obtained representing an average of 224,969 per sample (range
110 503−499 660). The overall quality of the sequencing run was
relatively low: if the quality (Phred) score cutoff was increased from 15
to 20, the approved number of sequences dropped to 674,989.
Regarding the phage selection process, the number of unique peptides
dropped with each subsequent round. Specifically, from 4938 to 410 for
round one to three for the toxin-selected samples and similarly from 413
to 108 from rounds three to five in the control samples.
Themost frequent peptide sequence identified in deep sequencing of
the third selection round was identical to peptide 1, a known binder
from phage display/ELISA, suggesting that frequently occurring
sequences in this round could be potential binders. Accordingly,
three additional peptides (peptides 7, 3, and 5 in Table 1) ranking
second through fourth in frequency in round three were selected for
further studies. Another peptide, 8, was included because it ranked
seventh in round three and was consistently prevalent in the later
rounds. The most frequent peptide in the first selection round, 6, was
also selected. Finally, a peptide ranking sixth in the third round, 4, was
included because it was highly similar to 8 differing only in 3 C-terminal
amino acids out of the 20-mer peptide.
Electrophysiological Assays. Stage V/VI Xenopus laevis oocytes
were prepared as described previously34 and under license 2014-15-
0201-00031 from the Danish Veterinary and Food Administration.
Oocytes were injected with a volume of 40 nL containing 4 ng of cRNA
for α7 nicotinic acetylcholine receptor (rat) carrying the L247V
mutation to reduce desensitization35 and 4 ng of cRNA for the
chaperone RIC-3 (human), which enhances acetylcholine receptor
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function.36 cRNAs were prepared and oocytes were maintained as
described previously.34 One to 3 days after injecting, two electrode
voltage clamp recordings were made as follows: A single oocyte was
transferred to a custom recording chamber37 and continuously perfused
with bath solution (in mM; 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5
HEPES, pH 7.4, with NaOH). The oocyte was impaled with
borosillicate glass micropipettes containing 3 M KCl (resistance
∼0.5−1.5 MΩ), membrane voltage was clamped at −40 mV, and
current recorded with OC-725C amplifier (Warner Instruments),
Digidata 1550 digitizer, and pClamp 10 Software (Molecular Devices)
at 1 kHz with 200 Hz filtering. Replicate experiments were generally
performed on four individual oocytes (see Quantification and Statistical
Analysis below). Solution exchange was performed with a ValveBank 8
perfusion system (AutoMate Scientific). ACh and α-Cbtx were
prepared from stocks dissolved in water (100 mM and 10 μM,
respectively, stored at −20 °C). Peptide (1−18) stocks of 10 mM were
prepared in bath solution and typically used within 1 week (if not used
in 1 day, these were stored at −20 °C). Peptides were mixed with α-
Cbtx 20 min to 1.5 h before application to oocytes. Current amplitude
wasmeasured in Clampfit 10 (pClamp,Molecular Devices) and current
amplitude was plotted and analyzed in GraphPad Prism 7.
Peptides. All peptides used for subsequent assays, except 9, were
purchased from Schafer-N (Copenhagen, Denmark) or GenScript,
≥95% purity (Supporting Information, Figures S5−S22). The 5(6)-
carboxytetramethylrhodamine (TAMRA)-labeled peptide 9 was
synthesized using an automated peptide synthesizer and standard
Fmoc (fluorenylmethoxycarbonyl)-based solid-phase peptide synthesis
(SPPS) on Rink amide TentaGel resin (0.23 mmol/g) at a 0.02 mmol
scale. Fmoc deprotections were performed in two steps: (1) piperidine
in DMF (2:3, v/v) for 3 min and (2) piperidine in DMF (1:4, v/v) for
12 min. Deprotection steps were followed by washing with DMF (2 ×
45 s), CH2Cl2 (1 × 45 s), and DMF (2 × 45 s). Coupling steps were
performed as double couplings with Fmoc-Xaa-OH (5.00 equiv to the
resin loading), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronoium
hexafluorophosphate (HBTU) (4.90 equiv), and i-Pr2NEt in NMP
(10.0 equiv, 2.0M) inDMF (final concentration = 0.2M for Fmoc-Xaa-
OH) for 40 min for each coupling. Glycine was incorporated as N-α-
Fmoc-N-α-(2,4-dimethoxybenzyl)-glycine (Fmoc-(Dmb)Gly-OH).
TAMRA-acid (1.50 equiv) was coupled manually using 2-(1H-7-
azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronoium hexafluorphos-
phate (HATU) (1.50 equiv) and i-Pr2NEt (3.00 equiv) in DMF
(final concentration = 0.06 M) for 16 h. Global deprotection and
cleavage was conducted in the cleavage cocktail (TFA−i-Pr3SiH−
water, 95:2.5:2.5, v/v/v) at room temperature (RT) for 2 h, followed by
TFA evaporation and ether precipitation. The crude peptide was
purified as single isomer by preparative reverse-phase high performance
liquid chromatography (RP-HPLC) on a C8 Phenomenex Luna
column (5 μm, 100 Å, 250 mm × 20 mm) using an Agilent 1260 LC
system. Fractions were analyzed by matrix assisted laser desorption
ionization−time-of-flight mass spectrometry (MALDI-TOF MS), and
pure fractions were pooled and lyophilized. Purity was determined
using an Agilent 1100 system equipped with C18 Phenomenex Luna
column (2.6 μm, 100 Å, 150 mm × 4.60 mm). Analytical HPLC purity
95% (λ = 215 nm; Figure S13). UPLC-MS m/z calcd for
C124H157N27O30S2
2+ [M + 2H]2+: 1284.55, found 1284.38;
C124H158N27O30S2
3+ [M + 3H]3+: 856.70, found 856.82;
C124H159N27O30S2
4+ [M + 4H]4+: 642.78, found 642.91 (Supporting
Information, Figure S13).
Fluorescence Polarization (FP) Assays. Protein concentrations
and DMSO stock concentrations of unlabeled peptides were
determined by UV absorbance (NanoDrop OneC, ThermoFisher
Scientific) at 280 nm. The DMSO stock of TAMRA ligand (9) was
determined by weight of the corresponding TFA salt (MW+ 5×TFA =
3138 g/mol). Binding affinities were determined in a 384-well plate
format (Corning Life Science) using a Safire 2 plate reader (Tecan).
The instrument G-factor was calibrated to give an initial millipolariza-
tion at 20 (excitation at 530 nm; emission at 580 nm) and the
instrumental Z-factor was adjusted to maximum fluorescence. All
measurements were conducted in phosphate-buffered saline (PBS, pH
= 7.4) at 25 °C. In a FP saturation assay, 50 nM of 9 was mixed with
increasing concentrations (0.125−213 μM) of α-Cbtx. The resulting
polarization was plotted as a function of the protein concentration and
fitted to a one-site binding model GraphPad Prism 7.0 software to yield
the Kd at 50% saturation. The binding experiment was performed as a
single experiment with two replicates. FP competition experiments
were conducted by mixing a preformed α-Cbtx:9 complex at fixed
concentration (40 μM/50 nM) with varying unlabeled peptide
concentrations ranging from 0.2−1024 μM. The polarization (mP)
was plotted as a function of peptide concentration and fitted to a
sigmoidal dose response curve using GraphPad Prism 7 software. The
Ki values were calculated according to the equations by Nikolovska-
Coleska et al.38 The Ki values were determined form three individual
experiments performed with two replicates.
[ ] + + [ ] × [ ] − [ ] =P K L P P( ) ( ) 00
2
d T 0 T (1)
[ ] = [ ] − [ ]PL P P0 T 0 (2)
[ ] = [ ] − [ ]L L PL0 T 0 (3)
[ ] = [ ] ×PL PL 1/250 0 (4)
[ ] = [ ] − [ ]L L PL50 T 50 (5)
[ ] = − [ ] + × [ ] [ ] + [ ]I P K PL L PLIC /50 50 T d 50 50 50 (6)
= [ ] [ ] + [ ] +K I L K P K/( / / 1)i 50 50 d 0 d (7)
P, protein (α-Cbtx); L, ligand (TAMRA-peptide 9); I, inhibitor
(peptide 1 or 12); Kd, dissociation constant of the protein−ligand
complex; [P]T, total protein concentration; [L]T, total ligand
concentration; [P]0, unbound protein concentration at 0% inhibition;
[L]0, unbound ligand concentration at 0% inhibition; [PL]0, protein−
ligand complex concentration at 0% inhibition; [P]50, unbound protein
concentration at 50% inhibition; [L]50, unbound ligand concentration
at 50% inhibition; [PL]50, protein−ligand complex concentration at
50% inhibition; [I]50, unbound inhibitor concentration at 50%
inhibition; IC50, half maximal inhibitory concentration; Ki, dissociation
constant of the protein−inhibitor complex.
Crystallization and Structure Determination. α-Cbtx (lyophi-
lized powder, ≥99%, Latoxan) and 12 (≥95%, GenScript) were
solubilized in 20 mMHEPES, pH 7.2, 100 mMNaCl at concentrations
of 14.4 mg mL−1 (1.87 mM) and 8.2 mg mL−1 (5.5 mM), respectively,
and mixed at 1:1.2 molar ratio. Crystallization trays were set up with a
semiautomated pipetting robot (Gryphon, Art Robbins Instruments).
Best crystals grew in 0.1 M carboxylic acids (sodium formate/
ammonium acetate/sodium citrate/sodium potassium tartrate/sodium
oxamate), 0.1 M HEPES/MOPS, pH 7.5, 30.0% v/v PEG 500 MME/
PEG 20000 (Morpheus Crystallization Screen, Molecular Dimensions)
and were directly flash frozen in liquid nitrogen. Data sets were
collected at beamline MX14.2, BESSY Berlin39 and beamline P13,
EMBL Hamburg, respectively. Diffraction data was processed with
XDSAPP40,41 and initial phases were obtained by molecular
replacement using phenix.phaser42 with the neurotoxin-1 from Naja
naja oxiana (PDB 1NTN,43 as a search model. A molecular model for
the peptide portion of 12 could be built unambiguously into the
remaining difference density. The final model was obtained through
iterative cycles of model building in Coot44 and refinement with
refmac/phenix.refine42,45 and is deposited at the protein database
(PDB 6ZFM).
Quantification and Statistical Analysis. In Phage display
screening, sequencing identified only two peptide binders of α-Cbtx,
and both were characterized further. InDeep sequencing of phage libraries
and selection of an additional six peptides for testing, several more
potential peptide binders were identified, but only six were selected for
further characterization based on their amino acid sequence identity
with proven binders from Phage Display Screening.
Data from Electrophysiological assays are mean ± SEM (n = 2−4
oocytes in Figure 1B; n = 3 oocytes in Figure 2A,B; and n = 2−5 in
Supporting Information, Figure S1B, as indicated in figure legends).We
have chosen to show SEM error bars for the few groups where n = 2, as
this shows the range of these data. To establish that, e.g., peptide 1
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prevented α-Cbtx from inhibiting acetylcholine-gated currents through
acetylcholine receptors, we compared the mean current amplitude
(relative to control) in the presence of α-Cbtx to the mean current
amplitude (relative to control) in the presence of both α-Cbtx and
peptide 1, using a two-tailed unpaired t test (GraphPad Prism).
In FP assays, the binding saturation with 9 and α-Cbtx was
performed as a single experiment with two replicates. For competition
with 1 and 12, Ki values were determined from three individual
experiments performed with two replicates. Data are given as mean ±
SEM Ki values were calculated according to Nikolovska-Coleska et al.
38
and compared using a two-tailed unpaired t test (GraphPad Prism).
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